Porovnat metody
Prohlédněte si vybrané metody vedle sebe; řádky, které se liší, jsou zvýrazněny.
| Analýza izobologramů× | Metoda Chou-Talalay× | Schildova analýza× | |
|---|---|---|---|
| Obor | Farmakologie | Farmakologie | Farmakologie |
| Rodina | Process / pipeline | Process / pipeline | Process / pipeline |
| Rok vzniku≠ | 1926 | 1983 | 1947 |
| Tvůrce≠ | Salvatore Loewe | Ting-Chao Chou and Paul Talalay | Henry Schild |
| Typ≠ | synergy quantification | synergy quantification | antagonism quantification |
| Původní zdroj≠ | Loewe, S. (1926). Die Mischtoxizität. Zeitschrift für Experimentelle Pathologie und Therapie, 24, 315-334. link ↗ | Chou, T. C., & Talalay, P. (1983). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation, 22, 27-55. DOI ↗ | Schild, H. O. (1947). pA, a new scale for the measurement of drug antagonism. Journal of Physiology, 106(3), 337-357. DOI ↗ |
| Další názvy≠ | isobol, combination index, synergy testing | CI method, Chou method, median-effect analysis | Schild plot, pA2 |
| Příbuzné | 3 | 3 | 3 |
| Shrnutí≠ | Isobologram analysis is a graphical and quantitative method for detecting and classifying drug interactions, developed by Salvatore Loewe in 1926. It uses dose-response data from two drugs applied individually and in combination to determine whether their interaction is additive, synergistic, or antagonistic. | The Chou-Talalay method is a quantitative framework for analyzing drug interactions, developed by Ting-Chao Chou and Paul Talalay in 1983. It combines median-effect principle with the combination index (CI) to provide rigorous, model-independent assessment of synergistic, additive, or antagonistic drug effects. | Schild analysis is a quantitative method for characterizing competitive receptor antagonism developed by Henry Schild in 1947. It uses dose-response curves in the presence and absence of antagonist to estimate the antagonist affinity constant (pA2), enabling standardized comparison of antagonist potency across drugs and experimental systems. |
| ScholarGateDatová sada ↗ |
|
|
|